Business 2.0 Ranks Aeroflex Among America's Fastest Growing Companies.Business & High Tech Editors PLAINVIEW, N.Y.--(BUSINESS WIRE)--Oct. 7, 2002 Business 2.0 magazine has ranked Aeroflex Incorporated, (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ARXX) a leading designer, developer and manufacturer of microelectronics and automated testing (testing) automated testing - Software testing assisted with software tools that require no operator input, analysis, or evaluation. solutions for the broadband communications market, number 52 on its recent list of the 100 fastest-growing technology companies. The list appeared in the October 2002 edition. The publication's management selected Aeroflex from a list of over 2,000 publicly traded tech companies. Zacks Investment Research Zacks Investment Research A firm that compiles earnings estimates and brokerage firm investment recommendations for thousands of publicly traded firms. compiled the list of 2,000 publicly traded tech companies for Business 2.0, from which five percent qualified. The criteria used by the publication in making its selections included a combination of revenue, earnings, stock market performance and growth in cash flow. This ranking follows on the heels of another award received by Aeroflex - Top Performing Small Company as announced in Aviation Week's Top-Performing Aerospace Rankings (July 1, 2002). Aeroflex's growing sales and improved profits took them from the No. 5 position in 2001 to No. 1 in 2002. "We are very proud of both these rankings," said Len Borow, Executive Vice President/COO of Aeroflex. "It is our vision to be the industry leader in our core businesses by focusing on total customer satisfaction. These awards show that a commitment to total customer satisfaction can and does positively impact growth." About Aeroflex Aeroflex Incorporated, through its subsidiaries, designs, develops and manufactures state-of-the-art microelectronic module, integrated circuit integrated circuit (IC), electronic circuit built on a semiconductor substrate, usually one of single-crystal silicon. The circuit, often called a chip, is packaged in a hermetically sealed case or a nonhermetic plastic capsule, with leads extending from it for , interconnect (1) To attach one device to another. (2) A physical port (plug, socket) or wireless port (transmitter, receiver) used to attach one device to another. and testing solutions used in broadband communication applications. The Company's common stock trades on the Nasdaq National Market System under the symbol ARXX and is included in the S&P SmallCap 600 index. Additional information concerning Aeroflex Incorporated can be found on the Company's Web site: www.aeroflex.com. All statements other than statements of historical fact included in this press release regarding Aeroflex's financial position, business outlook, business strategy and plans and objectives of its management for future operations are forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. . When used in this press release, words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to Aeroflex or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of Aeroflex's management, as well as assumptions made by and information currently available to its management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to, competitive factors and pricing pressures, changes in legal and regulatory requirements Regulatory requirements are part of the process of drug discovery and drug development. Regulatory requirements describe what is necessary for a new drug to be approved for marketing in any particular country. , technological change or difficulties, product development risks, the integration of IFR IFR abbr. instrument flight rules Systems with Aeroflex, the implementation of the facilities consolidations, commercialization difficulties and general economic conditions. Such statements reflect our current views with respect to the future and are subject to these and other risks, uncertainties and assumptions relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc Aeroflex's financial condition, results of operations, growth strategy and liquidity. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion